- 2022.02.01Axcelead Begins Joint Research with Tokyo Medical and Dental University on mRNA Drug Development for Acute Cerebral Infarction and Postresuscitation Encephalopathy Press Release
- 2022.01.12IP Generator, Axcelead, and Axcelead Drug Discovery Partners Signed a Comprehensive Business Alliance Agreement Press Release
- 2021.12.16Hitachi and Axcelead DDP Launch Manufacturing Process Development Support Service for Cell Therapy and Gene Therapy – Supporting optimization of product development and manufacturing with automation and quality assessment Press Release
- 2021.12.02Axcelead and FRONTEO Started the Joint Project “Druggable Target 1000” to Evaluate Drug Targets with AI ― Dramatically Increase Efficiency of Drug Discovery Business by Comprehensively and Objectively Analyzing the Potential of Drug Targets Press Release
- 2021.11.25Axcelead DDP was rated as “Excellent” by Japan Agency for Medical Research and Development (AMED) in a program for “Drug Discovery Seeds Development”, which demonstrates Axcelead DDP’s ability of integrated and high-quality drug discovery research. Press Release